# Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

> **NCT00248534** · PHASE2 · TERMINATED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 16 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** methylprednisolone
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00248534
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-09
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** slow accrual/lack of resources/low priority due to combining 2 consortia
- **Last updated:** 2018-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00248534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00248534, "Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00248534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*